Maplight Therapeutics (NASDAQ:MPLT) Director Acquires $186,301.84 in Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director George Pavlov bought 10,658 shares of Maplight Therapeutics stock in a transaction dated Wednesday, February 18th. The stock was acquired at an average cost of $17.48 per share, with a total value of $186,301.84. Following the transaction, the director owned 10,658 shares of the company’s stock, valued at $186,301.84. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

George Pavlov also recently made the following trade(s):

• On Friday, February 20th, George Pavlov purchased 9,920 shares of Maplight Therapeutics stock. The shares were acquired at an average cost of $17.86 per share, for a total transaction of $177,171.20.
• On Thursday, February 19th, George Pavlov acquired 4,422 shares of Maplight Therapeutics stock. The stock was acquired at an average cost of $17.57 per share, with a total value of $77,694.54.

Maplight Therapeutics Price Performance

Shares of MPLT opened at $17.88 on Monday. Maplight Therapeutics, Inc. has a 12 month low of $12.24 and a 12 month high of $21.55. The stock’s 50 day simple moving average is $17.93. The company has a market capitalization of $811.22 million and a PE ratio of -0.48.

Maplight Therapeutics (NASDAQ:MPLT) last issued its quarterly earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Hedge Funds Weigh In On Maplight Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Strs Ohio bought a new stake in shares of Maplight Therapeutics during the fourth quarter worth $53,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Maplight Therapeutics during the 4th quarter valued at $70,000. New York State Common Retirement Fund bought a new stake in Maplight Therapeutics during the 4th quarter worth $93,000. MetLife Investment Management LLC bought a new stake in Maplight Therapeutics during the 4th quarter worth $172,000. Finally, Walleye Capital LLC bought a new position in Maplight Therapeutics in the fourth quarter valued at about $205,000.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on MPLT. Morgan Stanley began coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They set an “overweight” rating and a $34.00 price objective for the company. Jefferies Financial Group assumed coverage on shares of Maplight Therapeutics in a research report on Friday, November 21st. They issued a “buy” rating and a $32.00 target price for the company. Zacks Research upgraded shares of Maplight Therapeutics to a “hold” rating in a research report on Monday, November 24th. Wall Street Zen upgraded shares of Maplight Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. Finally, Weiss Ratings started coverage on Maplight Therapeutics in a report on Thursday, January 22nd. They issued a “sell (e)” rating on the stock. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.00.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.